Bionomics Limited (ASX:BNO)
CEO & Managing Director Dr Deborah Rathjen presents at ASX Spotlight Series in New York.
The biopharmaceutical company’s presentation is titled, “Global leader in drug discovery and development”.
Ms Rathjen discusses Bionomics’ value proposition, partnered programs and in-house development programs.
Discussing the company’s value proposition Ms Rathjen says, “We have a very broad and deep pipeline which I will walk through as I go through this presentation.
And, this pipeline provides us with multiple opportunities for development and also for strategic partnering.
We have a very strong cash position. 31 December cash was just over $38 million and this leaves us in a position to be able to support in a rapid and unencumbered way the development of our programs.”